Entera Bio ENTX 深 沪
交易中 08-24 11:08:22 美东时间
3.285
+0.055
+1.70%
华盛通- 最 高3.33
- 今 开3.28
- 成交量 5.35万股
- 最 低 3.20
- 昨 收 3.23
- 总市值 5.69亿
- 52周最高 4.20
- 市盈率 静 --
- 换手率 0.03%
- 52周最低 0.91
- 委 比 -42.86%
- 总股本 1.73亿
- 历史最高 10.16
- 量 比 0.58
- 振 幅 4.02%
- 历史最低 0.472
- 每 手 1
- 风险率 0.60%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Entera Bio appoints new chief medical officer
The latest announcement is out from Entera Bio ( ($ENTX) ). On August 18, 2026,...
08-18 20:29
Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation
Entera Bio Ltd. has appointed Riccardo Camisasca, M.D., as its Chief Medical Officer. With over 30 years of experience in global pharmaceutical research and clinical development, Dr. Camisasca previously served as Global Head of Research & Development at Sumitomo Pharma Switzerland. His expertise will strengthen Entera’s clinical execution team and support the upcoming Phase 3 initiation of EB613, an oral anabolic treatment for osteoporosis. Dr. ...
08-18 12:00
Entera Bio Announces That Post-Hoc Data From Its Phase 2 Clinical Trial Of EB613Has Been Selected For Two Presentations At The American Society For Bone And Mineral Research Annual Meeting
Two presentations including the Plenary Poster Presentation at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting, taking place October 9–12, 2026, at the John B. Hynes Veterans Memorial Convention Center in Boston, Massachusetts. Plenary Posters are highly ranked poster ...
08-04 20:32
美股牛股 | QBTS飙升20%，与AT&T达成量子计算合作；奥麦罗制药劲升15%，阿斯利康竞品药物3期临床试验失败
QBTS飙升20%，与AT&T达成量子计算合作；奥麦罗制药劲升15%，阿斯利康竞品药物3期临床试验失败；BMNR大涨13%，旗下以太坊价值已超公司原本市值>>
07-28 18:45
Entera Bio prices $275M private placement
Entera Bio (NASDAQ:ENTX) said on Monday it priced an oversubscribed $275M private placement led by existing investor BVF Partners, with participation from several healthcare-focused institutional inve...
07-27 20:59
Entera Bio Enters Into Securities Purchase Agreement For Oversubscribed Private Placement Financing, Expected To Result In Aggregate Gross Proceeds Of ~$275M
Expected gross proceeds are anticipated to extend the Company's cash runway into 2030 and fully support Phase 3 registrational studies for EB613, the first oral PTH(1-34) peptide tablet in development for the treatment of osteoporosis TEL AVIV, July 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASD...
07-27 20:33
Entera Bio Expands Share Authorization and Equity Plans
Entera Bio ( ($ENTX) ) has issued an announcement. At its 2026 Annual Meeting o...
07-17 17:15
Reported Earlier: Entera Bio Receives FDA's Positive Feedback For Its Phase 3 Registrational Protocol For EB613 Tablet In Development To Treat Osteoporosis
Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today announced that it has received positive feedback from the U.S. Food and Drug Administration (FDA) on its Phase 3 registrational protocol for EB613 (oral PTH(1-34), teriparatide), the first...
06-23 00:32
Entera Bio Presents Oral Presentation Titled Transforming Anabolic Treatments For Osteoporosis: Reports Phase 1 Data Showing Single-Tablet EB613 Matches Forteo PK/PD Profile
Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today reported comparative Phase 1 data evaluating single-tablet and multi-tablet oral EB613 with Forteo® (teriparatide SC injection, Eli Lilly). The oral presentation "Transforming Anabolic Trea...
06-15 20:50
Entera Bio Announces Presentations Of New Data Supporting Its Oral Peptide Pipeline At The Annual Endochrine Society Meeting On June 13-16
Abstract Title: Transforming Anabolic Treatments for Osteoporosis: New Clinical Data Supports a Single EB613 Tablet [Oral PTH(1-34)] as the Final Candidate for a Phase 3 StudySession Title: Late-Breaking Oral
05-28 20:54
